FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure
Stefan D. Anker, MD, PhD
Mahir Karakas, MD, PhD, MBA
NYHA FC and Finerenone Response: Clinical Trial Insights
John Ostrominski
Complexities in ATTR-CM Care: Key Considerations for Accurate Diagnosis
Gautam Nayak, MD
Advances in Care for ATTR-CM: Current and Emerging Strategies
Treating ATTR-CM: Current Strategies and Emerging Options
Frederick Ruberg, MD
Addressing Unmet Needs in ATTR-CM Care: Key Considerations for Optimal Management
Michelle Kittleson, MD, PhD
Overcoming Challenges in ATTR-CM Care: Best Practices for Accurate Diagnosis
Understanding the Pathophysiology Behind ATTR-CM
Cost-Effectiveness of Universal vs. Selective Screening for ATTR-CM in HFpEF Patients
Kibum Kim, PhD
ATTR-CM Screening: How Economic Factors Can Impact Care
Patient Case: ATTRwt-CM Discovered Decades After Heart Transplant
Lily Stern, MD
AF and VTE: Global Considerations in the Evolving Space of Real-World Data
Renato D. Lopes, MD, MHS, PhD
Valeria Caso, MD, PhD
Alexander T. Cohen, MD, MBBS
Setting the Stage of Real-World Data vs RCT
Trade off: Ischemic/Thrombotic vs Bleeding
Implications Associated With Integrating Both Real-World Data and Clinical Trial Data Into Clinical Practice: AF Considerations
How Do We Translate Real-World AF Data Into Everyday Clinical Practice?
Loading...
NEW FEATURES:
Tell us what you think by using our Feedback button
We're glad to see you're enjoying Global Cardiology Academy… but how about a more personalized experience?
Press cancel to remain on Global Cardiology Academy. Press the link below or the continue button to keep going.